American Journal of Obstetrics and Gynecology
Transactions of the Twenty-Fifth Annual Meeting of the Society for Maternal-Fetal MedicineAn elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia
Section snippets
Study design
A case-control study was designed with stored amniotic fluid and maternal plasma obtained from women who underwent mid-trimester genetic amniocentesis between July 1998 and April 2004 at Seoul National University Hospital in Seoul, Korea. The case group consisted of pregnant women who subsequently developed preeclampsia. The control group consisted of women who had a normal pregnancy outcome (term gestation with a neonate with adequate weight for gestational age).
Thirty-two patients who
Results
The clinical characteristics of the study population are shown in Table I. There were no statistically significant differences in the mean maternal age, parity, gestational age at amniocentesis and blood sampling, indication for amniocentesis, maternal weight, and body mass index between patients who developed preeclampsia and those in the control group.
Table II demonstrates the clinical characteristics of patients with preeclampsia at the time of diagnosis. Among cases with preeclampsia, 18
Comment
Our data indicate that the median mid-trimester maternal plasma sFlt-1 concentration in patients who subsequently developed preeclampsia was significantly higher than in those who had a normal pregnancy outcome and an elevated maternal plasma sFlt-1 concentration (higher than 700 pg/mL) is associated with an increased risk for the development of severe preeclampsia (OR 7.4, 95% CI 2.5-22.1).
As to the mean sFlt-1 concentration of normal pregnant women, there are some variations among several
References (19)
- et al.
Recent insights into the pathogenesis of pre-eclampsia
Placenta
(2002) - et al.
Preeclampsia: an excessive maternal inflammatory response to pregnancy
Am J Obstet Gynecol
(1999) - et al.
Trophoblast deportation in human pregnancy—its relevance for pre-eclampsia
Placenta
(1999) - et al.
Soluble vascular endothelial growth factor receptor-1(sFlt-1) is increased throughout gestation in patients who have preeclampsia develop
Am J Obstet Gynecol
(2004) - et al.
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award
Am J Obstet Gynecol
(2004) - et al.
Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia
Obstet Gynecol
(2000) - et al.
Hypertension in pregnancy
Curr Opin Obstet Gynecol
(1993) Endothelial dysfunction in preeclampsia
Semin Reprod Endocrinol
(1998)- et al.
Excess placental soluble fms-like tyrosine kinase 1(sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
J Clin Invest
(2003)
Cited by (0)
This study was supported by a grant 01-PJ1-PG1-01CH07-0002 from the 2001 Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea.
Presented at the Twenty-Fifth Annual Meeting of the Society for Maternal Fetal Medicine, February 7-12, 2005, Reno, Nev.